CLAIMS

1. Use of a compound according to Formula I in the manufacture of a medicament for the treatment of a disease caused by a disturbance in the activity of the androgen receptor, wherein Formula I is defined as:



Formula I

in which;

R_1 and R_2 are the same or different and independently selected from the group consisting of; hydrogen, halogen, C_1-C_{10} alkyl, C_1-C_{10} substituted alkyl, C_2-C_{10} alkenyl, C_2-C_{10} alkynyl, C_1-C_{10} alkoxy, C_1-C_{10} alkenoxy, C_1-C_{10} alkynoxy, C_1-C_{10} alkylthio, C_1-C_{10} alkenylthio, C_1-C_{10} alkynylthio, C_6-C_{10} arylthio, C_1-C_{10} alkylsulphone, C_1-C_{10} alkenylsulphone, C_1-C_{10} alkynylsulphone, C_6-C_{10} arylsulphone, C_1-C_{10} alkylsulphoxide, C_1-C_{10} alkenylsulphoxide, C_1-C_{10} alkynylsulphoxide, C_6-C_{10} arylsulphoxide, C_1-C_{10} alkylarylthio, C_1-C_{10} alkylarylsulphone, C1-C_{10} alkylarylsulphoxide, C_6-C_{10} aryl, or C_5-C_{20} heteroaryl, optionally substituted with 0, 1, 2 or 3 groups of R^a which groups may be the same or different; or R_1 and R_2 may together form a C_3-C_{10} cycloalkyl group;

R_3 and R_4 are the same or different and independently selected from hydrogen, halogen, C_1-C_{20} alkyl, C_3-C_7 cycloalkyl, C_2-C_4 alkenyl, C_2-C_4 alkynyl, C_1-C_4 alkoxy, C_1-C_4 alkenoxy, C_1-C_4 alkynoxy, C_1-C_4 alkylthio, C_1-C_4 alkenylthio, C_1-C_4 alkynylthio C_1-C_{10} alkylsulphone, C_1-C_{10} alkenylsulphone, C_1-C_{10} alkynylsulphone, C_6-C_{10} arylsulphone, C_1-C_{10} alkylsulphoxide, C_1-C_{10} alkenylsulphoxide, C_1-C_{10} alkynylsulphoxide, C_6-C_{10} arylsulphoxide, C_1-C_{10} alkylarylthio, C_1-C_{10} alkylarylsulphone, C_1-C_{10} alkylarylsulphoxide, C_6-C_{15} aryl, C_5-C_{20} heteroaryl optionally substituted with 0, 1, 2 or 3 groups of R^a which groups may be the same or different; or can together form a keto group;

R_5 is chosen from the group consisting of; nitro, cyano, -CH_2CN, -COMe, acetic acid, halogen, sulphonic acid, -SO_2CH_3, aldehyde, carboxylic acid or ester, phosphonic acid or ester;

R_6 is chosen from the group consisting of; hydrogen, C_1-C_5 alkyl, halogen, CN, CO_2H, CHF_2, CH_2F or CF_3;

R_7 is chosen from the group consisting of; H, halogen or C_1-C_5 alkyl;

R_8 is chosen from the group consisting of; hydrogen, C_1-C_5 alkyl, halogen, CHF_2, CH_2F or CF_3;

X is chosen from the group consisting of; –NH-, -O-, -S-, -SO-, $-SO_2$, -Se-, -Te- or –S-S-

Y is chosen from the group consisting of; hydrogen, hydroxy, -CH2OH, methoxy, NH_2, unbranched, branched or cyclic C_1-C_5 alkyl, unbranched, branched or cyclic -NH(C_1-C_8); unbranched, branched or cyclic $N(C_1-C_8)_2$, -NH(C_6aryl), $-N(C_6aryl)_2$, -NH(C_1-C_{10} heteroaryl), and $-N(C_5-C_{10}$ heteroaryl$)_2$, C_5-C_{10} heteroaryl wherein any of said aryl or heteroaryl groups are optionally substituted with up to 3 groups of R^a which groups may be the same or different;

Z is chosen from the group consisting of; C, N, or O;

R^a represents a member selected from: hydrogen, halogen, -CN, OH, CO_2H, CHO, NO_2, $-NH_2$, -NH(C_1-C_4); $N(C_1-C_4)_2$, -NH(C_6 aryl), $-N(C_6$ aryl$)_2$, -NH(C_5-C_{10} heteroaryl), and $-N(C_5-C_{10}$ heteroaryl$)_2$; or a pharmaceutically acceptable salt thereof.

2. Use according to claim 1, wherein R_1 or/and R_2 are H, (S)-methyl, methyl, (R)-ethyl, (S)-ethyl, ethyl, (R)-propyl, (S)-propyl, propyl, (S)-butyl, (S)-1-methyl-propyl, (S)-2-methyl-propyl, (R)-isopropyl, (S)-isopropyl, isopropyl, cyclopentyl, $-(CH_2)_2SMe$, (R)-CH_2SCH_2Ph, (S)-benzyl, 4-chloro-benzyl, (S)-3-methyl-1-H-indole or (S)-phenyl;

3. Use according to either of the preceding claims wherein R_3 is chosen from the group consisting of; hydrogen, methyl, ethyl, phenyl, 3-hydroxy phenyl, 4-hydroxy phenyl, or forms a keto group together with R_4.

4. Use according to any of the preceding claims wherein R_4 is H, methyl, or forms a keto group together with R_3.

5. Use according to any of the preceding claims wherein R_5 is NO_2, CN, CH_2CN or CO_2H;

6. Use according to any of the preceding claims wherein R_6 is Me, or CF_3;

7. Use according to any of the preceding claims wherein R_7 is H or Me;

8. Use according to any of the preceding claims wherein R_8 is H or methyl;

9. Use according to any of the preceding claims wherein X is NH;

10. Use according to any of the preceding claims wherein Y is H, -OH, -OMe, $-N(CH_2CH_3)_2$, piperidine, or 4-nitro-2-ylamino;

11. Use according to any of the preceding claims wherein Z is CR_9 or N;

12. Use according to any of the preceding claims wherein the compound is chosen from the group consisting of;

2-Methyl-2-(4-nitro-3-trifluoromethyl-phenylamino)-propan-1-ol;
[1-(4-Nitro-3-trifluoromethyl-phenylamino)-cyclopentyl]-methanol;
(S)-2-(4-Nitro-3-trifluoromethyl-phenylamino)-3-phenyl-propan-1-ol;

(S)-2-(4-Nitro-3-trifluoromethyl-phenylamino)-butan-1-ol;

2-Methyl-2-(3-hydroxy-4-nitro-phenylamino)-propan-1-ol;

[1-(3-Methyl-4-nitro-phenylamino)-cyclopentyl]-methanol;

(S)-2-(3-Methyl-4-nitro-phenylamino)-butan-1-ol;

2-Methyl-2-(6-methyl-5-nitro-pyridine-2-ylamino)-propan-1-ol;

[1-(6-Methyl-5-nitro-pyridine-2-ylamino)-cyclopentyl]-methanol;

(S)-2-(6-Methyl-5-nitro-pyridin-2ylamino) 2-phenyl-ethanol;

(S) -2-(6-Methyl-5-nitro-pyridine-2-ylamino)-3-phenyl-propan-1-ol;

(S)-2-(6-Methyl-5-nitro-pyridin-2-ylamino)-butan-1-ol;

(DL) -3-(4-Chloro-phenyl)-2-(6-methyl-5-nitro-pyridin-2-ylamino)- -propan-1-ol;

(S)-2-(6-Methyl-5-nitro-2-pyridin-2-ylamino)-propionic acid;

(S)-2-(6-Methyl-5-nitro-pyridin-2-ylamino)-propan-1-ol;

2-(2,3-Dimethyl-4-nitro-phenylamino)-2-mehtyl-propan-1-ol;

(S)-2-(3,5-Dimethyl-4-nitro-phenylamino)-butan-1-ol;

4-(2-Hydroxy-1,1-dimethyl-ethylamino)-2-trifluoromethyl-benzonitrile;

4-(1-Hydroxymethyl-cyclopentylamino)-2-trifluoromethyl-benzonitrile;

(S)-4-(1-Hydroxymethyl-cyclopentylamino)-2-trifluoromethyl-benzonitrile;

(R)-4-(1-Hydroxymethyl-butylamino)-2-trifluoromethyl-benzonitrile;

(S)-4-(1-Hydroxymethyl-butylamino)-2-trifluoromethyl-benzonitrile;

[4-((S)-1-Hydroxymethyl-butylamino)-2-trifluoromethyl-phenyl]-acetonitrile;

[4-((R)-1-Hydroxymethyl-butylamino)-2-trifluoromethyl-phenyl]-acetonitrile;

[4-((S)-1-Hydroxymethyl-3-methyl-butylamino)-2-trifluoromethyl-phenyl]-acetonitrile;

4-(2-Hydroxy-1,1-dimethyl-ethylamino)-2-methyl-benzonitrile;

6-(2-Hydroxy-1,1-dimethyl-ethylamino)-2-methyl-nicotinonitrile;

4-(2-Hydroxy-1,1-dimethyl-ethylamino)-2,3-dimethyl-benzonitrile;

and compounds having the formula:



in which R_9, R_6 and Z are as defined in the following table:

R9	R6	Z
	CF_3	CH
	CF_3	CH
	CF_3	CH
	CF_3	CH
	CF_3	CH
	CF_3	CH
	CF_3	CH
	CF_3	CH

R9	R6	Z		
	CF_3	CH		
	CF_3	CH		
	CF_3	CH		
	CF_3	CH		
	CF_3	CH		
	CF_3	CH		
	CF_3	CH		
	CF_3	CH		
	CF_3	CH		

R9	R6	Z
	CF_3	CH
	CF_3	CH
	CF_3	CH
	CF_3	CH
	CF_3	CH
	CF_3	CH
	CH_3	N
	CH_3	N
	CH_3	N

R9	R6	Z
	CH_3	N
	CH_3	N
	CH_3	N
	CH_3	N
	CH_3	N
	CH_3	N
	CH_3	N
	CH_3	N
	CH_3	N

R9	R6	Z
	CH_3	N
	CH_3	N
	CH_3	N
	CH_3	N
	CH_3	N
	CH_3	N
	CH_3	N
	CH_3	N
	CH_3	N
	CH_3	N
	CH_3	CH

R9	R6	Z		
	CH_3	CH		
	CH_3	CH		
	CH_3	CH		
	CH_3	CH		
	CH_3	CH		
	CH_3	CH		
	CH_3	CH		
	CH_3	CH		
	CH_3	CH		
	CH_3	CH		
	CH_3	CH		

R9	R6	Z			
	CH_3	CH			
	CH_3	CH			

4-(2-Hydroxy-1,1-dimethyl-ethylamino)-2-methyl-benzoic acid;

(6-Methyl-5-nitro-2-pyridin-2-ylamino)-butionic methyl ester;

2-Methyl-N-(6-methyl-5-nitro-pyridin-2-yl amino)-propan-2-ol;

4-((R)-2-Hydroxy-1-methyl-ethylamino)-2-trifluoromethyl-benzonitrile

4-((R)-1-Furan-2-ylmethyl-2-hydroxy-ethylamino)-2-trifluoromethyl-benzonitrile

(R)-3-Furan-2-yl-2-(6-methyl-5-nitro-pyridin-2-ylamino)-propan-1-ol

2-(6-Methyl-5-nitro-pyridin-2-ylamino)-heptan-1-ol

3-Cyclopentyl-2-(6-methyl-5-nitro-pyridin-2-ylamino)-propan-1-ol

2-(6-Methyl-5-nitro-pyridin-2-ylsulfanyl)-ethanol

[1-(4-Fluoro-3-methyl-phenylamino)-cyclopentyl]-methanol

1-[4-(2-Hydroxy-1,1-dimethyl-ethylamino)-2-trifluoromethyl-phenyl]-ethanone

1-[4-((S)-1-Hydroxymethyl-3-methyl-butylamino)-2-trifluoromethyl-phenyl]-ethanone

1-[4-(1-Hydroxymethyl-cyclopentylamino)-2-trifluoromethyl-phenyl]-ethanone

[1-(4-Methanesulfonyl-3-methyl-phenylamino)-cyclopentyl]-methanol

2,2-Dimethyl-3-(6-methyl-5-nitro-pyridin-2-ylamino)-propan-1-ol

2, 2-Dimethyl-3-(3-methyl-4-nitro-phenylamino)-propan-1-ol

4-((R)-1-Benzylsulfanylmethyl-2-hydroxy-ethylamino)-2-trifluoromethyl-benzonitrile

(R)-2-(6-Methyl-5-nitro-pyridin-2-ylamino)-3-phenylmethanesulfinyl-propan-1-ol

4-((R)-2-Hydroxy-1-phenylmethanesulfinylmethyl-ethylamino)-2-trifluoromethyl-benzonitrile

[1-(4-Nitro-phenylamino)-cyclopentyl]-methanol

(S)-2-(4-Nitro-phenylamino)-pentan-1-ol

(S)-4-Methyl-2-(4-nitro-phenylamino)-pentan-1-ol

[1-(2-Bromo-4-nitro-phenylamino)-cyclopentyl]-methanol

(S)-2-(2-Bromo-4-nitro-phenylamino)-pentan-1-ol

(S)-2-(2-Bromo-4-nitro-phenylamino)-4-methyl-pentan-1-ol

or a pharmaceutically acceptable salt thereof.

13. Use of compound according to claim 1, wherein R_1 or R_2 is a C_6-C_{10} arythio comprising an aryl-substituted sulfur-containing C_1-C_{10} alkyl group.

14. Use of a compound according to claim 1, wherein in R_1 or R_2 the alkylsulfur is substituted with a C_6 aryl group.

15. A pharmaceutical composition containing a compound as defined in Formula I of any preceding claim.

16. Use according to claim 1 wherein the disease is caused by an increase in androgen receptor activity.

17. Use according to any of claims 1-14 or 16 wherein the disease is chosen from the group consisting of, prostate cancer, lipid abnormalities, cardiovascular disease and psychological abnormalities, male pattern baldness (alopecia), benign prostatic hyperplasia (BPH) and acne, hirsutism, amenorrha, hypogonadism, anemia, diabetes, defects in spermatogenesis, cachexia, osteoporosis, osteopenia, and muscle wasting.

18. A compound as defined by Formula I :



Formula I

in which;

R_1 and R_2 are the same or different and independently selected from the group consisting of; hydrogen, halogen, C_1-C_{10} alkyl, C_1-C_{10} substituted alkyl, C_2-C_{10} alkenyl, C_2-C_{10} alkynyl, C_1-C_{10} alkoxy, C_1-C_{10} alkenoxy, C_1-C_{10} alkynoxy, C_1-C_{10} alkylthio, C_1-C_{10} alkenylthio, C_1-C_{10} alkynylthio, C_6-C_{10} arylthio, C_1-C_{10} alkylsulphone, C_1-C_{10} alkenylsulphone, C_1-C_{10} alkynylsulphone, C_6-C_{10} arylsulphone, C_1-C_{10} alkylsulphoxide, C_1-C_{10} alkenylsulphoxide, C_1-C_{10} alkynylsulphoxide, C_6-C_{10} arylsulphoxide, C_1-C_{10} alkylarylthio, C_1-C_{10} alkylarylsulphone, C1-C_{10} alkylarylsulphoxide, C_6-C_{10} aryl, or C_5-C_{20} heteroaryl, optionally substituted with 0, 1, 2 or 3 groups of R^a which groups may be the same or different; or R_1 and R_2 may together form a C_3-C_{10} cycloalkyl group;

R_3 and R_4 are the same or different and independently selected from hydrogen, halogen, C_1-C_{20} alkyl, C_3-C_7 cycloalkyl, C_2-C_4 alkenyl, C_2-C_4 alkynyl, C_1-C_4 alkoxy, C_1-C_4 alkenoxy, C_1-C_4 alkynoxy, C_1-C_4 alkylthio, C_1-C_4 alkenylthio, C_1-C_4 alkynylthio C_1-C_{10} alkylsulphone, C_1-C_{10} alkenylsulphone, C_1-C_{10} alkynylsulphone, C_6-C_{10} arylsulphone, C_1-C_{10} alkylsulphoxide, C_1-C_{10} alkenylsulphoxide, C_1-C_{10} alkynylsulphoxide, C_6-C_{10} arylsulphoxide, C_1-C_{10} alkylarylthio, C_1-C_{10} alkylarylsulphone, C_1-C_{10}

alkylarylsulphoxide, C_6-C_{15} aryl, C_5-C_{20} heteroaryl optionally substituted with 0, 1, 2 or 3 groups of R^a which groups may be the same or different; or can together form a keto group;

R_5 is chosen from the group consisting of; nitro, cyano, -CH_2CN, -COMe, acetic acid, halogen, sulphonic acid, -SO_2CH_3, aldehyde, carboxylic acid or ester, phosphonic acid or ester;

R_6 is chosen from the group consisting of; hydrogen, C_1-C_5 alkyl, halogen, CN, CO_2H, CHF_2, CH_2F or CF_3;

R_7 is chosen from the group consisting of; H, halogen or C_1-C_5 alkyl;

R_8 is chosen from the group consisting of; hydrogen, C_1-C_5 alkyl, halogen, CHF_2, CH_2F or CF_3;

X is chosen from the group consisting of; –NH-, -O-, -S-, -SO-, -SO_2, -Se-, -Te- or –S-S-

Y is chosen from the group consisting of; hydrogen, hydroxy, -CH2OH, methoxy, NH_2, unbranched, branched or cyclic C_1-C_5 alkyl, unbranched, branched or cyclic -NH(C_1-C_8); unbranched, branched or cyclic $N(C_1$-$C_8)_2$, -NH(C_6aryl), -$N(C_6aryl)_2$, -NH(C_1-C_{10} heteroaryl), and -$N(C_5$-C_{10} heteroaryl)$_2$, C_5-C_{10} heteroaryl wherein any of said aryl or heteroaryl groups are optionally substituted with up to 3 groups of R^a which groups may be the same or different;

Z is chosen from the group consisting of; C, N, or O;

R^a represents a member selected from: hydrogen, halogen, -CN, OH, CO_2H, CHO, NO_2, -NH_2, -NH(C_1-C_4); $N(C_1$-$C_4)_2$, -NH(C_6 aryl), -$N(C_5$ aryl)$_2$, -NH(C_5-C_{10} heteroaryl), and -$N(C_5$-C_{10} heteroaryl)$_2$; or a pharmaceutically acceptable salt thereof.

with the proviso that the compound is not:



19. A compound according to claim 18, wherein R_1 or/and R_2 are H, (S)-methyl, methyl, (R)-ethyl, (S)-ethyl, ethyl, (R)-propyl, (S)-propyl, propyl, (S)-butyl, (S)-1-methyl-propyl, (S)-2-methyl-propyl, (R)-isopropyl, (S)-isopropyl, isopropyl, cyclopentyl, -$(CH_2)_2SMe$, (R)-CH_2SCH_2Ph, (S)-benzyl, 4-chloro-benzyl, (S)-3-methyl-1-H-indole or (S)-phenyl;

20. A compound according to either of claims 18 and 19, wherein R_3 is chosen from the group consisting of; hydrogen, methyl, ethyl, phenyl, 3-hydroxy phenyl, 4-hydroxy phenyl, or forms a keto group together with R_4.

21. A compound according to any of claims 18-20, wherein R_4 is H, methyl, or forms a keto group together with R_3.

22. A compound according to any of claim 18-21, wherein R_5 is NO_2, CN, CH_2CN or CO_2H;

23. A compound according to any of claims 18-22, wherein R_6 is Me, or CF_3.

24. A compound according to any of claims 18-23, wherein R_7 is H or Me.

25. A compound according to any of claims 18-24, wherein R_8 is H or methyl.

26. A compound according to any of claims 18-25, wherein X is NH.

27. A compound according to any of claims 18-26, wherein Y is H, -OH, -OMe, -N$(CH_2CH_3)_2$, piperidime, or 4-nitro-2-ylamino.

28. A compound according to any of claims 18-27, wherein Z is CR_7 or N.

29. A compound according to any of claims 18-28, wherein the compound is chosen from the group consisting of:

2-Methyl-2-(4-nitro-3-trifluoromethyl-phenylamino)-propan-1-ol;
[1-(4-Nitro-3-trifluoromethyl-phenylamino)-cyclopentyl]-methanol;
(S)-2-(4-Nitro-3-trifluoromethyl-phenylamino)-3-phenyl-propan-1-ol;
(S)-2-(4-Nitro-3-trifluoromethyl-phenylamino)-butan-1-ol;
2-Methyl-2-(3-hydroxy-4-nitro-phenylamino)-propan-1-ol;
[1-(3-Methyl-4-nitro-phenylamino)-cyclopentyl]-methanol;
(S)-2-(3-Methyl-4-nitro-phenylamino)-butan-1-ol;
2-Methyl-2-(6-methyl-5-nitro-pyridine-2-ylamino)-propan-1-ol;
[1-(6-Methyl-5-nitro-pyridine-2-ylamino)-cyclopentyl]-methanol;
(S)-2-(6-Methyl-5-nitro-pyridin-2ylamino) 2-phenyl-ethanol;
(S) -2-(6-Methyl-5-nitro-pyridine-2-ylamino)-3-phenyl-propan-1-ol;
(S)-2-(6-Methyl-5-nitro-pyridin-2-ylamino)-butan-1-ol;
(DL) -3-(4-Chloro-phenyl)-2-(6-methyl-5-nitro-pyridin-2-ylamino)- -propan-1-ol;
(S)-2-(6-Methyl-5-nitro-2-pyridin-2-ylamino)-propionic acid;
(S)-2-(6-Methyl-5-nitro-pyridin-2-ylamino)-propan-1-ol;
2-(2,3-Dimethyl-4-nitro-phenylamino)-2-mehtyl-propan-1-ol;
(S)-2-(3,5-Dimethyl-4-nitro-phenylamino)-butan-1-ol;
4-(2-Hydroxy-1,1-dimethyl-ethylamino)-2-trifluoromethyl-benzonitrile;
4-(1-Hydroxymethyl-cyclopentylamino)-2-trifluoromethyl-benzonitrile;
(S)-4-(1-Hydroxymethyl-cyclopentylamino)-2-trifluoromethyl-benzonitrile;
(R)-4-(1-Hydroxymethyl-butylamino)-2-trifluoromethyl-benzonitrile;
(S)-4-(1-Hydroxymethyl-butylamino)-2-trifluoromethyl-benzonitrile;
[4-((S)-1-Hydroxymethyl-butylamino)-2-trifluoromethyl-phenyl]-acetonitrile;
[4-((R)-1-Hydroxymethyl-butylamino)-2-trifluoromethyl-phenyl]-acetonitrile;
[4-((S)-1-Hydroxymethyl-3-methyl-butylamino)-2-trifluoromethyl-phenyl]-acetonitrile;
4-(2-Hydroxy-1,1-dimethyl-ethylamino)-2-methyl-benzonitrile;
6-(2-Hydroxy-1,1-dimethyl-ethylamino)-2-methyl-nicotinonitrile;
4-(2-Hydroxy-1,1-dimethyl-ethylamino)-2,3-dimethyl-benzonitrile;
and compounds having the formula:



in which R_9, R_6 and Z are as defined in the following table:

R9	R6	Z
	CF_3	CH
	CF_3	CH
	CF_3	CH
	CF_3	CH
	CF_3	CH
	CF_3	CH
	CF_3	CH
	CF_3	CH

R9	R6	Z		
	CF_3	CH		
	CF_3	CH		
	CF_3	CH		
	CF_3	CH		
	CF_3	CH		
	CF_3	CH		
	CF_3	CH		
	CF_3	CH		
	CF_3	CH		

R9	R6	Z
	CF_3	CH
	CF_3	CH
	CF_3	CH
	CF_3	CH
	CF_3	CH
	CF_3	CH
	CH_3	N
	CH_3	N
	CH_3	N

R9	R6	Z
	CH_3	N
	CH_3	N
	CH_3	N
	CH_3	N
	CH_3	N
	CH_3	N
	CH_3	N
	CH_3	N
	CH_3	N

R9	R6	Z
	CH_3	N
	CH_3	N
	CH_3	N
	CH_3	N
	CH_3	N
	CH_3	N
	CH_3	N
	CH_3	N
	CH_3	N
	CH_3	N
	CH_3	CH

R9	R6	Z		
	CH_3	CH		
	CH_3	CH		
	CH_3	CH		
	CH_3	CH		
	CH_3	CH		
	CH_3	CH		
	CH_3	CH		
	CH_3	CH		
	CH_3	CH		
	CH_3	CH		
	CH_3	CH		

R9	R6	Z			
	CH_3	CH			
	CH_3	CH			

4-(2-Hydroxy-1,1-dimethyl-ethylamino)-2-methyl-benzoic acid;

(6-Methyl-5-nitro-2-pyridin-2-ylamino)-butionic methyl ester;

2-Methyl-N-(6-methyl-5-nitro-pyridin-2-yl amino)-propan-2-ol;

4-((R)-2-Hydroxy-1-methyl-ethylamino)-2-trifluoromethyl-benzonitrile

4-((R)-1-Furan-2-ylmethyl-2-hydroxy-ethylamino)-2-trifluoromethyl-benzonitrile

(R)-3-Furan-2-yl-2-(6-methyl-5-nitro-pyridin-2-ylamino)-propan-1-ol

2-(6-Methyl-5-nitro-pyridin-2-ylamino)-heptan-1-ol

3-Cyclopentyl-2-(6-methyl-5-nitro-pyridin-2-ylamino)-propan-1-ol

2-(6-Methyl-5-nitro-pyridin-2-ylsulfanyl)-ethanol

[1-(4-Fluoro-3-methyl-phenylamino)-cyclopentyl]-methanol

1-[4-(2-Hydroxy-1,1-dimethyl-ethylamino)-2-trifluoromethyl-phenyl]-ethanone

1-[4-((S)-1-Hydroxymethyl-3-methyl-butylamino)-2-trifluoromethyl-phenyl]-ethanone

1-[4-(1-Hydroxymethyl-cyclopentylamino)-2-trifluoromethyl-phenyl]-ethanone

[1-(4-Methanesulfonyl-3-methyl-phenylamino)-cyclopentyl]-methanol

2,2-Dimethyl-3-(6-methyl-5-nitro-pyridin-2-ylamino)-propan-1-ol

2, 2-Dimethyl-3-(3-methyl-4-nitro-phenylamino)-propan-1-ol

4-((R)-1-Benzylsulfanylmethyl-2-hydroxy-ethylamino)-2-trifluoromethyl-benzonitrile

(R)-2-(6-Methyl-5-nitro-pyridin-2-ylamino)-3-phenylmethanesulfinyl-propan-1-ol

4-((R)-2-Hydroxy-1-phenylmethanesulfinylmethyl-ethylamino)-2-trifluoromethyl-benzonitrile

(1-(4-Nitro-phenylamino)-cyclopentyl]-methanol

(S)-2-(4-Nitro-phenylamino)-pentan-1-ol

(S)-4-Methyl-2-(4-nitro-phenylamino)-pentan-1-ol

[1-(2-Bromo-4-nitro-phenylamino)-cyclopentyl]-methanol

(S)-2-(2-Bromo-4-nitro-phenylamino)-pentan-1-ol

(S)-2-(2-Bromo-4-nitro-phenylamino)-4-methyl-pentan-1-ol

30. A compound according to any of claims 18-29, wherein R_1 or R_2 is a C_6-C_{10} arythio comprising an aryl-substituted sulfur-containing C_1-C_{10} alkyl group.

31. A compound according to any of claims 18-30, wherein in R_1 or R_2 the alkylsulfur is substituted with a C_6 aryl group.